<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540734</url>
  </required_header>
  <id_info>
    <org_study_id>A2750606</org_study_id>
    <nct_id>NCT01540734</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With PanadolÂ®</brief_title>
  <official_title>A Single Dose PK Study Investigating the Extent of Paracetamol Absorption From Two Sustained Release Paracetamol Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single dose pharmacokinetic study investigating two paracetamol formulations
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare bioavailability as measured by Area under the Curve in both fed and fasted states</measure>
    <time_frame>Visit 1 through Visit 3 (Day 13)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the effect of food on extent and rate of paracetamol absorption as measured by Area Under the Curve and Cmax</measure>
    <time_frame>Visit 1 through Visit 3 (Day 13)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess descriptive pharmacokinetic characteristics (Tmax, T1/2, AUC, Cmax)</measure>
    <time_frame>Visit 1 through Visit 3 (Day 13)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Marketed paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>marketed formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental paracetamol formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marketed paracetamol</intervention_name>
    <description>Marketed formulation</description>
    <arm_group_label>Marketed paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental paracetamol formulation</intervention_name>
    <description>Experimental formulation</description>
    <arm_group_label>Experimental paracetamol formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good general heatlh with (in the opinion of the investigator) no clinically
             significant and relevant abnormalities of medical history or physical examination

        Exclusion Criteria:

          -  Subject does not agree to refrain from alcohol consumption for the 10-day period prior
             to visit 2 and throughout the remainder of the study.

          -  Participation in another clinical study or receipt of an investigational drug within
             30 days of the screening visit.

          -  Current (within 14 days of screening) or regular use of any prescription, over the
             counter drugs including paracetamol/acetaminophen, herbal medicine or drug known to
             induce or inhibit hepatic drug metabolism in the 30 days prior to dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services NEBRASKA</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2012</study_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paracetamol</keyword>
  <keyword>pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

